CrossAssetDataThe Company File
···
LXRX

Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in The Woodlands, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $50 million and a loss of $50 million (its filed statements).

Product business Pharmaceutical Preparations The Woodlands, TX filings since 2000 8 of 9 filed, 1 estimated
Ask the desk about LXRX → Compare LXRX with FBIO → Price chart on TradingView ↗ Full EDGAR file ↗ Watch LXRX →

Sector peers: FBIOFHTXGOSSURGN

5.2/10headline grade
vs its business-model standard
3.4/10past 5.7/10present 6.2/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.2 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.4 out of ten, present 5.7 out of ten, future 6.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 3.5 out of ten. 1 warning event since 2017; the latest 2025-01-07. 35th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 3.6 out of ten. -5% a year over 10 filed years; profitable in 1 of 10. 36th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 3.1 out of ten. CrossAssetData estimate 3.1/10, confidence 35 of 100 (one part). 31st percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 5.2 out of ten. ROE -47%: lost 47¢ per shareholder dollar. Leverage 42%: owes 42¢ per asset dollar. 52nd percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 6.9 out of ten. top 31% of 314 in its family; net margin -101.1%. 69th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 4.9 out of ten. bottom 49% of 315 in its family for leadership; chief executive since 2024. 49th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 5.2 out of ten. top 48% of 272 in its family for room to expand. 52nd percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 7.7 out of ten. top 23% of 307 in its family for growth drivers. 77th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 6.0 out of ten. top 40% of 234 in its family for expectations against reality. 60th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-03-05 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form EFFECT, 2026-08-14. Filings on record since 2000. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: License 91%, Product 9%. As tagged in its annual report (Form 10-K, filed 2026-03-05).

Who runs it

Exton, Michael (Chief Executive Officer); Coiante, Scott M (SVP, Chief Financial Officer); Granowitz, Craig B (SVP, Chief Medical Officer); Crum, Brian T (SVP, General Counsel & Secr.); Defrancesco, Lisa (SVP, IR and Corp Comm); Gopinathan, Suma (SVP, Discovery); Martens, Rachel Yap (SVP, Partnerships & Corp Strat); Mcdermott, Wendy (SVP, Human Resources); Amouyal, Philippe (director); Barker, Sam L (director); and 16 more. 26 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.